ORBIMED ADVISORS LLC
CIK: 0001055951Latest portfolio: $4.9B · Q4 2025
Holdings
105
Total Value
$4.9B
New Positions
22
Closed Positions
20
Top Holdings
View All 105 Holdings →| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | EWTXEDGEWISE THERAPEUTICS INC | 15,518,492 | $385.1M | 7.86% | — | |
| 2 | LLYELI LILLY & CO | 301,200 | $323.7M | 6.61% | — | |
| 3 | BSXBOSTON SCIENTIFIC CORP | 2,419,300 | $230.7M | 4.71% | NEW | |
| 4 | SVASINOVAC BIOTECH LTD | 2,718,735 | $184.5M | 3.77% | — | |
| 5 | EWEDWARDS LIFESCIENCES CORP | 1,992,900 | $169.9M | 3.47% | NEW | Call |
| 6 | UPBUPSTREAM BIO INC | 5,693,589 | $154.6M | 3.16% | — | |
| 7 | ISRGINTUITIVE SURGICAL INC | 263,400 | $149.2M | 3.04% | -23,800 | |
| 8 | SIONSIONNA THERAPEUTICS INC | 3,561,655 | $146.5M | 2.99% | -143,304 | |
| 9 | MBXMBX BIOSCIENCES INC | 3,935,203 | $124.1M | 2.53% | -67,684 | |
| 10 | ARGXARGENX SE | 146,000 | $122.8M | 2.51% | -26,300 | |
| 11 | ELVNENLIVEN THERAPEUTICS INC | 7,959,538 | $122.6M | 2.50% | — | |
| 12 | ALNYALNYLAM PHARMACEUTICALS INC | 288,800 | $114.8M | 2.34% | -12,800 | |
| 13 | SYKSTRYKER CORPORATION | 325,000 | $114.2M | 2.33% | -34,200 | |
| 14 | SPRYARS PHARMACEUTICALS INC | 8,288,510 | $96.6M | 1.97% | — | |
| 15 | TERNTERNS PHARMACEUTICALS INC | 2,153,300 | $87.0M | 1.78% | -5,409,671 | |
| 16 | IRONDISC MEDICINE INC | 1,067,550 | $84.8M | 1.73% | -347,470 | |
| 17 | CAICARIS LIFE SCIENCES INC | 3,116,011 | $84.1M | 1.72% | +81K | |
| 18 | NTRANATERA INC | 365,800 | $83.8M | 1.71% | -63,500 | |
| 19 | CMPXCOMPASS THERAPEUTICS INC | 15,219,994 | $81.7M | 1.67% | — | |
| 20 | GPCRSTRUCTURE THERAPEUTICS INC | 1,161,803 | $80.8M | 1.65% | +23K | |
| 21 | DHRDANAHER CORPORATION | 299,800 | $68.6M | 1.40% | +37K | |
| 22 | CGONCG ONCOLOGY INC | 1,516,550 | $63.0M | 1.29% | -210,300 | |
| 23 | APLSAPELLIS PHARMACEUTICALS INC | 2,429,868 | $61.0M | 1.25% | NEW | |
| 24 | AVBPARRIVENT BIOPHARMA INC | 3,027,328 | $60.9M | 1.24% | — | |
| 25 | CITHE CIGNA GROUP | 205,000 | $56.4M | 1.15% | +42K |
Quarterly Changes
New Positions
Increased Positions
Sector Breakdown
HealthcareNaN% ($InfinityT)
Unknown0.0% ($51258164251039.4T)
Filing History
| Quarter | Filing Date | Portfolio Value | Holdings |
|---|---|---|---|
| Q4 2025 | Feb 17, 2026 | $4.9B | 108 |
| Q3 2025 | Nov 14, 2025 | $4.3T | 110 |
| Q2 2025 | Aug 14, 2025 | $4.0T | 103 |
| Q1 2025 | May 15, 2025 | $4.2T | 111 |
| Q4 2024 | Feb 14, 2025 | $4.9T | 119 |
| Q3 2024 | Nov 14, 2024 | $5503.5T | 119 |
| Q2 2024 | Aug 14, 2024 | $5064.5T | 115 |
| Q1 2024 | May 15, 2024 | $5460.0T | 115 |
| Q4 2023 | Feb 14, 2024 | $5007.2T | 111 |
| Q3 2023 | Nov 14, 2023 | $4707.6T | 128 |
| Q2 2023 | Aug 14, 2023 | $5518.9T | 127 |
| Q1 2023 | May 15, 2023 | $5094.0T | 125 |
| Q4 2022 | Feb 14, 2023 | $5227.5T | 116 |
| Q3 2022 | Nov 14, 2022 | $5.4T | 132 |
| Q2 2022 | Aug 15, 2022 | $5.5T | 145 |
| Q1 2022 | May 16, 2022 | $6.2T | 145 |
| Q4 2021 | Feb 14, 2022 | $7.8T | 159 |
| Q3 2021 | Nov 15, 2021 | $9.1T | 173 |
| Q2 2021 | Aug 16, 2021 | $9.9T | 160 |
| Q1 2021 | May 17, 2021 | $10.7T | 159 |
| Q4 2020 | Feb 16, 2021 | $11.4T | 149 |
| Q3 2020 | Nov 16, 2020 | $8.0T | 143 |
| Q2 2020 | Aug 14, 2020 | $7.1T | 135 |
| Q1 2020 | May 15, 2020 | $6.0T | 142 |
| Q4 2019 | Feb 14, 2020 | $7.0T | 136 |
| Q3 2019 | Nov 14, 2019 | $5.3T | 116 |
| Q2 2019 | Aug 14, 2019 | $6.5T | 128 |
| Q1 2019 | May 15, 2019 | $6.5T | 124 |
| Q4 2018 | Feb 14, 2019 | $5.4T | 131 |
| Q3 2018 | Nov 14, 2018 | $8.3T | 150 |
| Q2 2018 | Aug 14, 2018 | $8.4T | 147 |
| Q1 2018 | May 15, 2018 | $8.1T | 141 |
| Q4 2017 | Feb 14, 2018 | $7.9T | 133 |
| Q3 2017 | Nov 14, 2017 | $10.5T | 143 |
| Q2 2017 | Aug 14, 2017 | $9.5T | 138 |
| Q1 2017 | May 15, 2017 | $8.8T | 136 |
| Q4 2016 | Feb 14, 2017 | $7.8T | 132 |
| Q3 2016 | Nov 14, 2016 | $8.8T | 140 |
| Q2 2016 | Aug 15, 2016 | $9.6T | 137 |
| Q1 2016 | May 16, 2016 | $9.5T | 141 |
Fund Information
ORBIMED ADVISORS LLC is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $4.9B across 105 holdings. The largest position is EDGEWISE THERAPEUTICS INC (EWTX), representing 7.9% of the portfolio. Compared to the previous quarter, the fund opened 29 new positions and closed 28 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.